Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

Background Ipilimumab is an antibody that targets the cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor response. Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II non-small-cell lung cancer (NSCLC)...

Full description

Saved in:
Bibliographic Details
Published in:Invest New Drugs
Main Authors: Horinouchi, Hidehito, Yamamoto, Noboru, Fujiwara, Yutaka, Sekine, Ikuo, Nokihara, Hiroshi, Kubota, Kaoru, Kanda, Shintaro, Yagishita, Shigehiro, Wakui, Hiroshi, Kitazono, Satoru, Mizugaki, Hidenori, Tokudome, Takuto, Tamura, Tomohide
Format: Artigo
Language:Inglês
Published: Springer US 2015
Subjects:
Phase I Studies
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4491360/
https://ncbi.nlm.nih.gov/pubmed/25924991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0243-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items